This pseudotyped virus uses lentivirus packaging to carry full length HA, NA and M of Highly Pathogenic Avian Influenza (HPAI) A virus (A/Pelecanus/Peru/VFAR-140/2022(H5N1), clade 2.3.4.4b) (GenBank: OQ565628.1). The pseudotypes can be handled using BSL-2 containment practices.

• Applications:
• Anti-avian influenza virus neutralizing antibody screening at high throughput
• Anti-avian influenza virus drug screening at high throughput
• Avian influenza virus vaccine efficacy evaluation at high throughput
• Avian influenza virus pseudovirus transduction of target cells for viral entry, receptor recognition, cellular tropism and functional studies, such as ADCC analysis

Description: Infection of cells with this pseudotyped virus carrying luciferase reporter results in high level luciferase activity. See our titration result showing that the starting 2-fold diluted pseudovirus generates signal >100,000-fold higher than uninfected control (cell alone as background in blue). We also evaluated the neutralizing activity of one published neutralizing mAb 100F4 (Nat Commun. 2015:6:8855) and two control mAbs by using this pseudotyped virus.

Biosafety level: Handle it in biosafety cabinet in BSL-2. Contacted tips and tubes should be decontaminated by 10% disinfecting bleach.

Use protocol: A complete protocol is supplied with the shipping of product. Briefly, incubate 100 μl diluted virus with 100 μl your sample in each well of 96-well plate with at least one duplicate for 30 to 60 min at 37 °C. Then add 100 μl target cells (293T or other lung cells expressing receptor). Read luciferase signal next day. For protocol using reduced amount, incubate 40 μl diluted virus with 10 μl your sample in each well of 96-well plate for 30 to 60 min at 37 °C. Then add 25 μl target cells. Add 150 µl fresh media next day and read signal on Day 3.